Related Experiment Video
Updated: Jul 13, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Pleiotropic effects of cardilopin (secondary coronary prevention)
Insights
Cardilopin (Amlodipine) treatment improved coronary atherosclerosis by restoring endothelial function and reducing platelet aggregation. This suggests benefits for heart disease patients, including those with hypertension.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Coronary atherosclerosis is a significant health concern.
- Amlodipine is a commonly prescribed medication for hypertension.
- Pleiotropic effects of Amlodipine beyond blood pressure regulation warrant investigation.
Purpose of the Study:
- To evaluate the pleiotropic effects of Cardilopin (Amlodipine).
- To assess Cardilopin's impact on coronary atherosclerosis parameters in ambulatory patients.
Main Methods:
- 33 ambulatory patients were treated with Cardilopin (Amlodipine) for 2 months.
- Key parameters of coronary atherosclerosis, endothelial function, and platelet aggregation were monitored.
Main Results:
- Cardilopin treatment showed positive changes in coronary atherosclerosis parameters.
- Significant improvements were observed in endothelial function and inhibition of platelet aggregation.
- A trend towards reduced hyperlipoperoxidemia, linked to oxidative stress, was noted.
Conclusions:
- Cardilopin (Amlodipine) exhibits beneficial pleiotropic effects in patients with coronary atherosclerosis.
- The findings support the use of Cardilopin in coronary heart disease patients, irrespective of myocardial revascularization or arterial hypertension status.
Abstract:
In order to evaluate some pleiotropic effects of cardilopin (Amlodipine, EGIS Pharmaceuticals) 33 ambulatory patients were examined. During the 2-month study period on the background of cardilopin treatment there were positive changes in some parameters of coronary atherosclerosis. Pleiotropic effects of cardilopin were particularly expressed in restoring of endothelial function and inhibition of platelet aggregation. There was found tendency to reduce the degree of hyperlipoperoxidemia related to oxidative stress. Obtained results of the present trial support the use of cardilopin in all coronary heart disease patients with or without myocardial revascularization and arterial hypertension.
More Related Videos
10:03Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease IV: Preventive Measures
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy V: Interprofessional Care